Recombinant Zoster Vaccine (Shingrix) and GLP-1 Receptor Agonist for the Preservation of Beta-Cell Function in Adults With Recent-Onset Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial.

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by progressive destruction of pancreatic beta cells mediated by autoreactive T lymphocytes, resulting in absolute insulin deficiency. Preservation of residual beta-cell function at the time of diagnosis is a critical therapeutic window, as even marginal endogenous insulin secretion - reflected by detectable C-peptide levels - is associated with improved glycemic control, reduced hypoglycemia burden, and decreased long-term vascular complication rates.
This study evaluates the hypothesis that combinatorial immunomodulation - using the AS01B adjuvant system within the Recombinant Zoster Vaccine (RZV; Shingrix, GSK) alongside metabolic and cytoprotective support via a GLP-1 receptor agonist (semaglutide) - can synergistically preserve residual beta-cell function in adults within 100 days of T1D diagnosis. The AS01B adjuvant system activates innate immune pathways that promote regulatory T-cell (Treg) expansion and shift the immunological milieu toward tolerance, while GLP-1 receptor agonism provides direct beta-cell cytoprotection, reduces glucotoxicity, and may suppress autoimmune cytokine signaling.
SHIELD-T1D is a randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial enrolling 240 adults (18-50 years) diagnosed with T1D within 100 days, with confirmed residual beta-cell function (stimulated C-peptide ≥0.2 nmol/L). Participants are randomized 1:1:1:1 to one of four arms: (1) Shingrix alone, (2) Semaglutide alone, (3) Shingrix + Semaglutide combination, or (4) dual placebo. The primary endpoint is change in 2-hour stimulated C-peptide AUC during a Mixed Meal Tolerance Test (MMTT) from baseline to 12 months.
This phase II randomized, double-blind, placebo-controlled multicenter trial will evaluate the efficacy and safety of the recombinant zoster vaccine (Shingrix) and a glucagon-like peptide-1 (GLP-1) receptor agonist, alone and in combination, for preservation of residual beta-cell function in adults with recent-onset type 1 diabetes. The working hypothesis is that combining AS01 adjuvant-mediated immunomodulation with the metabolic and cytoprotective actions of a GLP-1 receptor agonist will provide dual protection for pancreatic beta cells, slowing autoimmune destruction and improving functional insulin secretion compared with placebo.

Start Date01 Jan 2027

Sponsor / Collaborator-

CTIS2025-521547-20-00

/ Active, not recruitingPhase 4IIT

Herpes zoster after recombinant herpes zoster vaccination - Immediate post-RHZ-vaccination evolution of CMI, HMI and lymphocyte count and typing.

Start Date01 Jun 2026

Sponsor / Collaborator

Centre Hospitalier Universitaire de Liege

NCT07485283

/ RecruitingPhase 4IIT

A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above

DAN-ZOSTER is a nationwide randomized study investigating whether vaccination against herpes zoster (shingles) can reduce the risk of cardiovascular disease and dementia in older adults. Herpes zoster is caused by reactivation of the varicella-zoster virus and becomes more common with increasing age. Some observational studies have suggested that vaccination against herpes zoster may also lower the risk of heart attacks, strokes, and dementia, but this has not been confirmed in randomized clinical trials.
In this study, approximately 162,000 adults aged 65 years or older living in Denmark will be randomly assigned to either receive the recombinant herpes zoster vaccine (Shingrix®) or receive no vaccine. Participants in the vaccine group will receive two doses given 2-6 months apart.
Participants will be identified and invited using Danish national registries and digital mail systems. Information about health outcomes will be collected through nationwide health registries during follow-up.
The main outcomes of the study are major cardiovascular events (heart attack, stroke, or cardiovascular death) and new diagnoses of dementia. The goal of the study is to determine whether herpes zoster vaccination can help prevent these conditions in older adults.

Start Date28 Apr 2026

Sponsor / Collaborator

Herlev and Gentofte Hospital

[+1]

100 Clinical Results associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

100 Translational Medicine associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

100 Patents (Medical) associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

3,862

Literatures (Medical) associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

31 Dec 2026·Expert Review of Vaccines

Fc-mediated immune effector functions elicited by recombinant and live-attenuated herpes zoster vaccines

Article

Author: Li, Jingxin ; Liang, Qi ; Huang, Zhuangzhuang ; Gan, Mingzhi ; Wei, Mingwei ; Zhai, Xiangjun ; Li, Simin ; Jin, Pengfei ; Pan, Hongxing

BACKGROUND:

The role of Fc-mediated immune responses in protecting against herpes zoster remains poorly understood. This study aimed to evaluate the Fc-mediated immune responses of anti-VZV glycoprotein E antibodies induced by two licensed varicella-zoster virus vaccines.

RESEARCH DESIGN AND METHODS:

We established two cohorts, each consisting of 48 healthy participants aged 50 or above, who received either the ZVL or RZV. Serum samples were measured to evaluate the Fc-mediated immune responses for antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and antibody-dependent neutrophil phagocytosis (ADNP) against VZV-gE. The correlations between Fc-mediated functions and the IgG levels were also analyzed.

RESULTS:

Both ZVL and RZV significantly induced Fc effector function responses against HZ in participants after vaccination. Compared with ZVL recipients, RZV recipients exhibited significantly higher increase-fold of ADCC responses (ZVL: 1.93-fold; RZV: 8.44-fold, p < 0.001). In each vaccine group, the younger recipients showed higher ADCC responses than did the older (ZVL: 2.17-fold vs. 1.45-fold, p = 0.0136; RZV: 8.93-fold vs. 7.43-fold, p = 0.0677). Similar patterns were observed for ADCP and ADNP responses.

CONCLUSION:

RZV induced superior Fc effector functions of VZV-gE antibodies compared to ZVL did. Older adults exhibited weaker Fc-mediated responses compared to younger adults following vaccination.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Predictors of initiation and completion of Shingrix vaccination in immunocompetent adults newly eligible for vaccination from 2018–2024

Article

Author: Masters, Nina B. ; Do, Duy ; Farrar, Karen Gilbert ; Cartwright, Brianna M. G.

The Shingrix vaccine has been recommended for immunocompetent adults aged ≥50 y since October 2017. It is important to assess recent trends and predictors of Shingrix vaccination among those newly eligible to evaluate acceptability, desirability, and uptake of the vaccine. In this retrospective cohort study, we used electronic health record data with linked medical and pharmacy claims data from Truveta. Immunocompetent adults turning 50 between 2018 and 2024 with at least 1 y of continuous enrollment after their 50th birthday were included. We estimated the cumulative incidence of vaccination by eligibility year and assessed series completion at 6 and 12 m. Multivariable logistic regression identified predictors of initiation and series completion. Among 153,899 adults (57.0% female; 62.2% White), 9.9% received ≥1 Shingrix dose within 1 y of eligibility. One-year uptake increased from 2.6% (2018 cohort) to 14.0% (2024 cohort). Three-year uptake reached 27.5% among those eligible in 2022. Among initiators within the first year of eligibility, 62.6% completed the series within 6 m and 74.5% within 12 m. Influenza vaccination during a person's 50th y was the strongest non time-based predictor of Shingrix vaccination (odds ratio 1.96, 95% CI 1.88-2.03). Women and Asian adults had higher odds of initiation, whereas Black or African American adults, Medicaid/CHIP enrollees, rural residents, and those with cardiovascular disease had lower odds. Shingrix uptake among newly eligible adults has increased rapidly since 2018. Persistent sociodemographic disparities highlight the need for targeted strategies to improve equitable vaccine uptake.

31 Dec 2026·Human Vaccines & Immunotherapeutics

TLR9 and STING agonists adjuvanted varicella-zoster virus glycoprotein E induced a potent and durable nasal vaccine response

Article

Author: Su, Yu-Wen ; Su, Yu-Siang ; Tien, Chih-Feng ; Yu, Guann-Yi ; Tseng, Jen-Chih ; Chuang, Tsung-Hsien ; Chen, Linyi ; Imana, Zaida Nur ; Yang, Jing-Xing ; Liu, Yi-Ling ; Lin, Po-Yen ; Tsai, Wan-Ting ; Huang, Ming-Hsi ; Chen, Jen-Kun

Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV), primarily affecting middle-aged and older individuals and often accompanied by severe pain and other complications. Vaccination is an effective preventive measure against this disease. In the present study, we evaluated the adjuvant activity of Toll-like receptor (TLR)9 and TLR7 agonists in combination with stimulator of interferon genes (STING) agonists for a VZV-glycoprotein E (gE)-based vaccine. Among the tested combinations, the CpG-2722 (TLR9 agonist) and 2'3'-c-di-AM(PS)2 (STING agonist) pairing exhibited potent immunostimulatory activity in immune cells and superior adjuvant activity for VZV-gE vaccines in a mouse models. Shingrix, a licensed herpes zoster vaccine, is administered intramuscularly. The CpG-2722/2'3'-c-di-AM(PS)2 combination adjuvanted VZV vaccine, administered intramuscularly, effectively induced higher gE-specific IgG responses than that induced by the Shingrix and imiquimod/2'3'-c-di-AM(PS)2 adjuvant vaccine. Notably, intranasal administration of the CpG-2722/2'3'-c-di-AM(PS)2 adjuvanted VZV vaccine to mice elicited a robust antigen-specific IgA response, which was barely detectable in intramuscularly administered vaccines. Two doses of the intranasal immunization, administered at a two-week interval, provided long-lasting protection, as antigen-specific IgG levels remained elevated for months without booster immunization. Further investigation into the functional mechanism revealed that CpG-2722 combined with 2'3'-c-di-AM(PS)2 induced a strong antigen-dependent T helper 1 (Th1) cytokine response, consistent with the antigen-independent cytokine-inducing properties of this adjuvant combination. This study demonstrates that the TLR9 and STING agonists formulated adjuvant induces a potent and long-lasting immune response, highlighting its potential as a promising adjuvant candidate for nasal VZV vaccines.

205

News (Medical) associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

24 Jun 2026

·www.prnewswire.com

New Study Suggests Shingles Vaccination May Be Associated with Reduced Dementia Risk in Older Adults

Research published in Annals of Internal Medicine uses PointClickCare Life Sciences' EHR data linked with Medicare claims to analyze outcomes in more than 500,000 individuals TORONTO, June 24, 2026 /PRNewswire/ -- New research published in Annals of Internal Medicine suggests that shingles vaccination may be associated with a reduced risk of dementia among older adults entering skilled nursing facilities. The study, led by researchers from Brown University School of Public Health and University of Delaware, evaluated outcomes in more than 500,000 adults aged 66 and older. Using Medicare claims linked with deidentified electronic health record (EHR) data from PointClickCare Life Sciences, the researchers conducted a target trial emulation to examine the relationship between the recombinant zoster vaccine (RZV) and the risk of developing dementia. "Older adults admitted to skilled nursing facilities represent a particularly vulnerable population, with elevated risk for both shingles and dementia," said Jeff Wessinger, vice president & GM of Life Sciences at PointClickCare. "However, this group is often underrepresented in traditional clinical research, making it difficult to generate evidence tailored to their care needs. We are proud that our longitudinal EHR data collected from the majority of long-term care (LTC) facilities in the U.S. can contribute to studies that will change outcomes for aging and vulnerable populations." The results showed that individuals who received at least one dose of the shingles vaccine within 12 months of entering a skilled nursing facility experienced a 24% relative reduction in dementia risk over four years, compared with those who were not vaccinated. "One of the strengths of this research was the ability to use linked Medicare and PointClickCare Life Sciences' EHR data to study older adults entering skilled nursing facilities," said Kaley Hayes, PharmD, PhD, assistant professor at Brown University School of Public Health and lead author of the study. "That combination gave us a real-world view of vaccination history, clinical characteristics, and outcomes in a population that is often underrepresented in traditional research." The study leveraged detailed, longitudinal clinical data captured within skilled nursing facilities, including resident demographics, assessments, medication administration records, and vaccination history. These data were linked with Medicare administrative claims to provide a comprehensive view of patient care before, during, and after facility admission. While the findings demonstrate a meaningful association between shingles vaccination and reduced dementia risk, the authors emphasize that further research, including randomized trials, will be needed to establish a causal relationship. The study also highlights persistently low uptake of shingles vaccination among older adults in skilled nursing settings. The research underscores the increasing role of real-world data in advancing evidence generation for aging populations. By enabling large-scale analyses in clinically complex populations, linked EHR and claims data can help researchers explore outcomes that are difficult to study in traditional trial settings. To learn more about our data, visit the website here. About the Study The study, Dementia Risk After Recombinant Herpes Zoster Vaccination in Older Adults With a Recent Skilled Nursing Facility Stay, is published in Annals of Internal Medicine. It used a target trial emulation design to estimate the association between RZV vaccination and incident dementia, drawing on linked Medicare claims and nursing home EHR data from PointClickCare. View the study abstract: View the patient summary: About PointClickCare Life Sciences PointClickCare Life Sciences partners with researchers and pharmaceutical organizations to accelerate the development, delivery, and evaluation of therapies for aging and vulnerable populations. Leveraging the most comprehensive real-world deidentified datasets derived from its widely adopted electronic health record (EHR) platform in long-term and post-acute care, PointClickCare Life Sciences provides deep, longitudinal insights into patient journeys, treatment patterns, and outcomes. This continuously updated, research-grade data captured as part of routine care enables life sciences organizations to inform clinical research, optimize commercialization strategies, and improve access to therapies for populations often underrepresented in traditional datasets. Media Contact Andie Morataya [email protected] SOURCE PointClickCare 21% more press release views with Request a Demo

VaccineClinical Result

26 May 2026

·www.fiercebiotech.com

Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues

The Vaccine Company buyout is potentially the most expensive of Lilly\'s three deals today.\n Eli Lilly has splashed up to $3.8 billion on an infectious disease pipeline, acquiring Curevo, LimmaTech Biologics and Vaccine Company to extend its buying spree into viral and bacterial pathogen R&D.The Big Pharma, which has been picking up biotechs on an almost weekly basis in recent months, disclosed its acquisition of the three infectious disease companies simultaneously on Tuesday morning. The takeovers “reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Daniel Skovronsky, M.D., Ph.D., chief scientific and product officer at Lilly, said in a statement.The Big Pharma is paying up to $1.5 billion, split between an upfront fee and a milestone payment, to buy shingles vaccine developer Curevo. Securing the biotech will position Lilly to challenge GSK, which sells the shingles vaccine Shingrix.Curevo designed its shingles vaccine candidate, amezosvatein, to improve on the tolerability of Shingrix. The biotech identified tolerability as an issue that deters people from receiving GSK\'s vaccine or discourages them from getting the second dose in the two-shot regimen. Curevo used a next-generation synthetic adjuvant to improve tolerability. In 2024, the biotech reported lower rates of local and systemic adverse events in a phase 2 trial that pitted amezosvatein against Shingrix. At the time, Curevo planned to enter phase 3 in 2024. The timeline slipped, with the biotech choosing to enroll a further 640 participants in a phase 2 extension in 2025. Curevo raised $110 million to fund the phase 2 extension last year.Meanwhile, the acquisition of LimmaTech gains Lilly vaccine candidates against bacterial pathogens. The deal, which could reach $780 million across both upfront and clinical and regulatory milestone payments, will give Lilly control of a pipeline led by a vaccine for Staphylococcus aureus that is in phase 1 development. Developing vaccines against pathogens such as S. aureus could help counter the emergence of strains that are resistant to antibiotics.The Vaccine Company buyout is potentially the most expensive of the three deals, with Lilly agreeing to pay up to $1.55 billion across an upfront fee and clinical and commercial milestones. In 2024, Vaccine Company received cash from the U.S. Advanced Research Projects Agency for Health (ARPA-H) to create vaccines against flaviviruses, a family of pathogens that includes West Nile virus, dengue virus and Zika virus.Vaccine Company has otherwise kept a low profile, quietly advancing technology designed to achieve the durable immune responses associated with virus-like particle vaccines while simplifying manufacturing. A five-antigen, phase 1-ready Epstein-Barr virus (EBV) vaccine candidate leads the biotech’s pipeline.Lilly’s statement about the deals emphasized the potential for the three biotechs’ programs to tackle the long-term consequences of certain viral and bacterial infections. Shingles is associated with an elevated risk of stroke, while EBV is linked to multiple sclerosis and several malignancies. The risks point to ways to make the clinical and commercial case for the vaccines at a time of pressure on vaccine manufacturers. With its focus on cancer, cardiometabolic health, immunology and neuroscience, Lilly has been protected from those pressures. But, flush with money from its GLP-1 juggernauts, the Big Pharma has decided to build on its infectious disease legacy by acquiring a vaccine pipeline. The deals come months after Lilly appointed former FDA leader Peter Marks, M.D., Ph.D., as head of infectious disease.

VaccineAcquisitionPhase 2Phase 1Clinical Result

26 May 2026

·firstwordpharma.com

Lilly bets more than $3.8B on vaccine triple play

Eli Lilly is expanding its R&D efforts in infectious diseases with the purchase of three vaccines companies — Curevo, LimmaTech Biologics and Vaccine Company — for a combined total of potentially more than $3.8 billion. "These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences," said Daniel Skovronsky, president of Lilly Research Laboratories.Shingles vaccineThe first deal involves Curevo and its lead product candidate amezosvatein (CRV-101), an adjuvanted subunit vaccine for the prevention of shingles in adults. Under the agreed terms, Curevo's shareholders could receive up to $1.5 billion in cash, inclusive of an undisclosed upfront payment and subsequent milestones.Lilly noted that while the current standard of care for shingles prevention is effective, tolerability challenges can limit the overall vaccination rates and contribute to second-dose hesitancy. To overcome this, amezosvatein has been engineered with a next-generation synthetic adjuvant — in a head-to-head Phase II study, Curevo's shot matched immune response versus GSK's Shingrix and reduced side effects such as activity-limiting fatigue, chills and pain at the injection site by more than half.With growing evidence linking shingles to an elevated risk of stroke, as well as a reduced dementia risk associated with shingles vaccination, Lilly is hoping that "a meaningfully better-tolerated vaccine could expand the reach of shingles prevention and reduce these long-term risks at a population level."Bacterial shotsVia another transaction, Lilly will boost its pipeline with a number of investigational vaccines from LimmaTech against bacterial pathogens that are facing rising antimicrobial resistance, including Staphylococcus aureus, Neisseria gonorrhoeae and Chlamydia trachomatis. The shots use LimmaTech's inhouse platform designed to generate broad, durable immune responses against complex bacterial targets by targeting the toxins and superantigens that drive disease.The company's lead programme, LTB-SA7, is in Phase I development as a vaccine against S. aureus, while its preclinical pipeline focuses on additional bacterial pathogens, including those that drive infertility and other long-term consequences of infection that fall disproportionately on women. Lilly will acquire LimmaTech for up to $780 million in cash, including an undisclosed upfront payment and further clinical and regulatory milestones.VLP alternativeMeanwhile, Lilly will also acquire Vaccine Company for up to $1.55 billion in cash, including an undisclosed upfront payment and certain clinical and commercial milestones.Vaccine Company is developing in vivo nanoparticle (IVN) technologies in an effort to avoid the manufacturing burden of traditional virus-like particle (VLP) vaccine production. Its preclinical pipeline is led by a five-antigen candidate vaccine for Epstein-Barr virus — an infection that is increasingly being linked to multiple sclerosis and several malignancies."Decades of evidence now link common infections to diseases that potentially emerge years later," Skovronsky said. "And as antimicrobial resistance erodes our ability to treat bacterial infections, vaccines are increasingly the only path to prevention. Combining these companies' platforms and teams with Lilly's global scale positions us to change that trajectory."

VaccineClinical ResultPhase 1AcquisitionPhase 2

100 Deals associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)	J07BK03	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neuralgia, Postherpetic	European Union	GlaxoSmithKline Biologicals SA	21 Mar 2018
Neuralgia, Postherpetic	Iceland	GlaxoSmithKline Biologicals SA	21 Mar 2018
Neuralgia, Postherpetic	Liechtenstein	GlaxoSmithKline Biologicals SA	21 Mar 2018
Neuralgia, Postherpetic	Norway	GlaxoSmithKline Biologicals SA	21 Mar 2018
Herpes Zoster	Canada	GlaxoSmithKline, Inc.	13 Oct 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ECCO2026	Not Applicable	Inflammatory Bowel Diseases	420	Recombinant zoster vaccine (RZV) Shingrix (Inflammatory bowel disease)	kyyfwrzbwn(mpquwshnmd) = wmqzqmcqhe dhojheffow (otfuvfurxp ) View more	Positive	18 Feb 2026
ASH2025	Not Applicable	Paraproteinemias	89	Recombinant adjuvanted zoster vaccine	ujsvxsonlr(lnywacrtue) = Adverse events due to vaccination included fever (n=32, 36.0%), pain (n=31, 34.8%) and redness (n=28, 31.5%) at the injection site while 4 (4.5%) patients reported none. oaescsssdy (lnmhswlima ) View more	Positive	06 Dec 2025
NCT06001606 (EULAR2025)	Phase 3	Systemic Lupus Erythematosus	60	HZ/su vaccine	pvhdelritt(tsrptyzikx) = lvcgrwklbn thsbfemsai (icvnmxavcj, 460.0 - 1775.8)	Positive	11 Jun 2025
EULAR2025	Not Applicable	Musculoskeletal Diseases	150	Recombinant zoster vaccine (RZV)	rtiupfqdxm(mirahsmayq) = By then, pain at the site of injection in 97 (32.7%) patients was the most frequent AE, followed by fever (42 (14.1%)), fatigue (28 (9.4%)), musculoskeletal pain (24 (8.1%)), swelling at the injection side (19 (6.4%)) and redness at the injection side (19 (6.4%)). Infections (14 (4.7%)), worsening of the disease (11 (3.7%) or other AEs (n=23 (7.7%) were reported until M3. hfybobzczg (pjwnccrbtr ) View more	Positive	11 Jun 2025
NCT04176939 (ERA2025)	Phase 3	Herpes Zoster	68	Recombinant zoster vaccine (RZV) (renal transplant)	wukjzgxmmo(mssdnohmle) = fmcvcxwjbf ihbakqrpyf (hlevawyogn ) View more	Positive	04 Jun 2025
NCT02723773 (ZOE-LTFU, Literature \| NEWS) Manual	Phase 3	Herpes Zoster	7,273	Herpes Zoster Vaccine GSK1437173A	elnnahafmw(jlqavbqrdi) = tcddughchx cpxlfbfegd (wmzgvcuzhg, 73.7 - 84.6) View more	Positive	12 May 2025
NCT04091451 (CTgov)	Phase 3	Herpes Zoster	1,430	Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) (HZ/su Group)	ygxfvijqwi = aovurwlpwi qdowyzfxdu (aafyuttjlv, wimrfkjlgr - nzxypyedve) View more	-	30 Mar 2025
NCT04091451 (CTgov)	Phase 3	Herpes Zoster	1,430	Placebo (Placebo Group)	ygxfvijqwi = jrodnezbxn qdowyzfxdu (aafyuttjlv, yhexojhgee - iuwzeaxsfu) View more	-	30 Mar 2025
NCT05219253 (Pubmed \| Vaccine)	Phase 3	Herpes Zoster Adjuvant	-	Adjuvanted Recombinant Zoster Vaccine (RZV)	ungunfzbjh(mctddjbcod) = qrrsrvaadc fuylauutiy (tmrnbulkno, 78.4 - 91.3)	Positive	01 Mar 2025
NCT03591770 (CTgov)	Phase 4	Colitis, Ulcerative	15	SHINGRIX (UC Patients on Tofacitinib Monotherapy)	pvlqrtgrip = chkwounrxs hwyzfumykx (hqfytjcgng, gyneleltck - lkjgtyqdyv) View more	-	21 Feb 2025
NCT03591770 (CTgov)	Phase 4	Colitis, Ulcerative	15	SHINGRIX (UC Patients on Anti-TNF Monotherapy)	pvlqrtgrip = ateqmcsppc hwyzfumykx (hqfytjcgng, rptqcjmvwy - tmmqhihonp) View more	-	21 Feb 2025
NCT05007041 (Pubmed \| JAMA Netw Open)	Phase 3	Herpes Zoster \| Influenza, Human	267	Adjuvanted Recombinant Zoster Vaccine (RZV) and Adjuvanted Inactivated Influenza Vaccine (aIIV4)	uycwbjmrqa(zafhpswjjt) = smpojxaarf fdioumrdfm (uvrhwefalr )	Positive	24 Oct 2024
NCT05007041 (Pubmed \| JAMA Netw Open)	Phase 3	Herpes Zoster \| Influenza, Human	267	Adjuvanted Recombinant Zoster Vaccine (RZV) and Quadrivalent High-Dose Inactivated Influenza Vaccine (HD-IIV4)	uycwbjmrqa(zafhpswjjt) = wtdrgqigvy fdioumrdfm (uvrhwefalr )	Positive	24 Oct 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation